Going Deeper Into Freenome

Due to the great work of researchers over the last decades, there are numerous drugs and surgical techniques to cure patients of cancer — if the cancer is caught early. And that’s notoriously hard to do, especially when symptoms often only arise in late stages of some of the most lethal cancers. For years, early detection has been the missing piece in the cure to many cancers. Existing tests are not sufficiently accurate, with many false positives and false negatives: 70% to 80% of men with an elevated PSA (prostate-specific antigen) who have a biopsy, for example, do not have cancer. Mammograms, too, were recently deprecated for younger women, due to unacceptably high false positive rates. Without higher accuracy, tests are useless in prevention.

Examining cell-free DNA has been a major breakthrough in recent years, with the most attention on examining tumor DNA. But in fact, only about 0.1% of cell-free DNA in cancer patients comes from tumors. That’s a needle in a haystack search problem. What’s the solution? For Freenome‘s cancer test, it’s looking at the whole haystack — for all kinds of changes. Our blood contains many additional analytes that indicate immunological and metabolic changes. So, for example, rather than only studying DNA fragments from tumor cells, Freenome has learned to decode complex signals coming from other cells in your immune system that change because of the tumor elsewhere.

How exactly can one identify which changes are associated with cancer? This is where machine learning shines, in particular deep learning. Much of the biological details here are complex, far too complex for typical approaches in biomarkers (looking for a specific gene or metabolite). Deep learning methods can quickly identify the relevant patterns (or “features”, to those performing machine learning) in a way that — because of the complexity — humans just couldn’t do.

This, however, leads to another challenge: how to train the machine learning methods. While these are powerful, they require data to learn these complex patterns. Freenome has developed a particularly valuable approach here, as they can work samples that others can’t, allowing them to build large datasets to achieve high accuracy.

This kind of approach marks a new era where machine learning allows us to embrace the complexity that permeates much of biology — without oversimplification, overfitting, or bias — resulting in considerably more accurate tests and earlier cancer detection.

I’m very pleased to announce that we are leading Freenome’s series A financing. Having worked with the company since leading their seed round, we have been delighted with their progress and with the quality of their team, including the original founders and the new hires since our last investment. We look forward to supporting Freenome as they continue and accelerate their novel research, expand to clinical trials, and bring their cancer screenings to market. 




The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation.

This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at https://a16z.com/investments/.

Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

Biology is eating the world

Sign up for our bio newsletter to get the a16z take on the future of biology and engineering.